Organogenesis Holdings Inc., a regenerative medicine company, focuses on the development, manufacture, and commercialization of solutions for the advanced wound care, and surgical and sports medicine markets primarily in the United States.
Concerning outlook with worrying balance sheet.
Share Price & News
How has Organogenesis Holdings's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ORGO's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: ORGO underperformed the US Biotechs industry which returned 27.6% over the past year.
Return vs Market: ORGO underperformed the US Market which returned 9.5% over the past year.
Price Volatility Vs. Market
How volatile is Organogenesis Holdings's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StAn Intrinsic Calculation For Organogenesis Holdings Inc. (NASDAQ:ORGO) Suggests It's 40% Undervalued
2 months ago | Simply Wall StUS$8.50: That's What Analysts Think Organogenesis Holdings Inc. Is Worth After Its Latest Results
2 months ago | Simply Wall StAre Insiders Buying Organogenesis Holdings Inc. (NASDAQ:ORGO) Stock?
Is Organogenesis Holdings undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ORGO's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate ORGO's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ORGO is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: ORGO is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ORGO's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ORGO is overvalued based on its PB Ratio (10.8x) compared to the US Biotechs industry average (3.6x).
How is Organogenesis Holdings forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ORGO is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ORGO is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ORGO is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ORGO's revenue (11.6% per year) is forecast to grow faster than the US market (8.8% per year).
High Growth Revenue: ORGO's revenue (11.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ORGO is forecast to be unprofitable in 3 years.
How has Organogenesis Holdings performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ORGO is currently unprofitable.
Growing Profit Margin: ORGO is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ORGO is unprofitable, and losses have increased over the past 5 years at a rate of -19.8% per year.
Accelerating Growth: Unable to compare ORGO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ORGO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).
Return on Equity
High ROE: ORGO has a negative Return on Equity (-102%), as it is currently unprofitable.
How is Organogenesis Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: ORGO's short term assets ($111.4M) exceed its short term liabilities ($54.8M).
Long Term Liabilities: ORGO's short term assets ($111.4M) do not cover its long term liabilities ($113.2M).
Debt to Equity History and Analysis
Debt Level: ORGO's debt to equity ratio (230.9%) is considered high.
Reducing Debt: Insufficient data to determine if ORGO's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ORGO has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: ORGO has less than a year of cash runway if free cash flow continues to reduce at historical rates of 38.5% each year
What is Organogenesis Holdings's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ORGO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ORGO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ORGO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ORGO's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ORGO's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Gary Gillheeney (64yo)
Mr. Gary S. Gillheeney, Sr. serves as the Chief Executive Officer and President of Organogenesis Inc., since 2014 and has been its Director since December 10, 2018. Mr. Gillheeney served as Organogenesis's ...
CEO Compensation Analysis
Compensation vs Market: Gary's total compensation ($USD1.44M) is below average for companies of similar size in the US market ($USD2.21M).
Compensation vs Earnings: Gary's compensation has been consistent with company performance over the past year.
|VP & General Counsel||3.33yrs||US$508.71k||no data|
|Chief Commercial Officer||2.58yrs||US$605.80k||0.0031% $13.5k|
|Chief Financial Officer||3.58yrs||no data||no data|
|Chief Operating Officer||2.58yrs||no data||0.11% $503.0k|
|Vice President of Human Resources||1.83yrs||no data||no data|
|Senior Vice President of Quality Systems||12.33yrs||no data||no data|
Experienced Management: ORGO's management team is considered experienced (3.3 years average tenure).
|Director||1.42yrs||no data||7.5% $32.9m|
|Director||1.42yrs||no data||14.08% $61.7m|
|Chairman of the Board||no data||no data||8.94% $39.2m|
|Director||1.42yrs||no data||no data|
Experienced Board: ORGO's board of directors are not considered experienced ( 1.4 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 16.2%.
Organogenesis Holdings Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Organogenesis Holdings Inc.
- Ticker: ORGO
- Exchange: NasdaqCM
- Founded: 1985
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$438.226m
- Shares outstanding: 106.11m
- Website: https://organogenesis.com
Number of Employees
- Organogenesis Holdings Inc.
- 85 Dan Road
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ORGO||NasdaqCM (Nasdaq Capital Market)||Yes||Class A Common Stock||US||USD||Jan 2019|
|2PQ||DB (Deutsche Boerse AG)||Yes||Class A Common Stock||DE||EUR||Jan 2019|
Organogenesis Holdings Inc., a regenerative medicine company, focuses on the development, manufacture, and commercialization of solutions for the advanced wound care, and surgical and sports medicine markets primarily in the United States. The company’s advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for treating DFUs; PuraPly AM to address biofilm across a range of wound types; and Affinity and NuShield to address various wound sizes and types. Its surgical and sports medicine products comprise ReNu for in-office joint and tendon applications; NuCel for bony fusion in the spine and extremities; NuShield and Affinity for surgical applications in targeted soft tissue repairs; and PuraPly AM for the surgical treatment of open wounds. The company’s pipeline products include TransCyte for the treatment of second- and third-degree burns; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; Novachor for the treatment of chronic and acute wounds; Gintuit for the treatment of mucogingival conditions in adults; and PuraPly XT and PuraPly MZ for the treatment of chronic and acute wounds, as well as for surgical treatment of open wounds. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices. The company sells its products through direct sales representatives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/05/31 06:44|
|End of Day Share Price||2020/05/29 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.